The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited

Hellman, 1995, Oligometastases, J Clin Oncol, 13, 8, 10.1200/JCO.1995.13.1.8 Pitroda, 2018, Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis, Nat Commun, 9, 1793, 10.1038/s41467-018-04278-6 Khodarev, 2015, microRNAs and oligometastasis, Aging, 7, 146, 10.18632/aging.100731 Uppal, 2015, 14q32-encoded microRNAs mediate an oligometastatic phenotype, Oncotarget, 6, 3540, 10.18632/oncotarget.2920 Adson, 1984, Resection of hepatic metastases from colorectal cancer, Arch Surg, 119, 647, 10.1001/archsurg.1984.01390180015003 Gomez, 2019, Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study, J Clin Oncol, 37, 1558, 10.1200/JCO.19.00201 Iyengar, 2018, Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial, JAMA Oncol, 4, 10.1001/jamaoncol.2017.3501 Palma, 2019, Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial, Lancet, 393, 2051, 10.1016/S0140-6736(18)32487-5 Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853 Phillips, 2020, Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial, JAMA Oncol, 6, 650, 10.1001/jamaoncol.2020.0147 Abida, 2017, Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making, JCO Precis Oncol, 1 Hamid, 2019, Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer, Eur Urol, 76, 89, 10.1016/j.eururo.2018.11.045 Abida, 2019, Genomic correlates of clinical outcome in advanced prostate cancer, Proc Natl Acad Sci U S A, 116, 11428, 10.1073/pnas.1902651116 Scher, 2016, Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3, J Clin Oncol, 34, 1402, 10.1200/JCO.2015.64.2702 Robinson, 2015, Integrative clinical genomics of advanced prostate cancer, Cell, 161, 1215, 10.1016/j.cell.2015.05.001 Grasso, 2012, The mutational landscape of lethal castration-resistant prostate cancer, Nature, 487, 239, 10.1038/nature11125 Espiritu, 2018, The evolutionary landscape of localized prostate cancers drives clinical aggression, Cell, 173, 10.1016/j.cell.2018.03.029 Fraser, 2017, Genomic hallmarks of localized, non-indolent prostate cancer, Nature, 541, 359, 10.1038/nature20788 Cancer Genome Atlas Research Network, 2015, The molecular taxonomy of primary prostate cancer, Cell, 163, 1011, 10.1016/j.cell.2015.10.025 Vandekerkhove, 2019, Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer, Eur Urol, 75, 667, 10.1016/j.eururo.2018.12.042 Stopsack, 2020, Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer, Clin Cancer Res, 26, 3230, 10.1158/1078-0432.CCR-20-0168 Lo, 2017, The role and mechanism of epithelial-to-mesenchymal transition in prostate cancer progression, Int J Mol Sci, 18, 2079, 10.3390/ijms18102079 Malek, 2017, TWIST1-WDR5-Hottip regulates Hoxa9 chromatin to facilitate prostate cancer metastasis, Cancer Res, 77, 3181, 10.1158/0008-5472.CAN-16-2797 Singh, 2004, Is there a favorable subset of patients with prostate cancer who develop oligometastases?, Int J Radiat Oncol Biol Phys, 58, 3, 10.1016/S0360-3016(03)01442-1 Kneebone, 2018, Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography, Eur Urol Oncol, 1, 531, 10.1016/j.euo.2018.04.017 Siva, 2018, Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial, Eur Urol, 74, 455, 10.1016/j.eururo.2018.06.004 Perera, 2016, Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis, Eur Urol, 70, 926, 10.1016/j.eururo.2016.06.021 Chang, 2020, Treating oligometastatic disease with SABR: more than just a numbers game?, Int J Radiat Oncol Biol Phys, 107, 257, 10.1016/j.ijrobp.2020.02.018 Parker, 2018, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial, Lancet, 392, 2353, 10.1016/S0140-6736(18)32486-3 Mateo, 2020, Genomics of lethal prostate cancer at diagnosis and castration resistance, J Clin Invest, 130, 1743, 10.1172/JCI132031 Isaacsson Velho, 2019, Efficacy of radium-223 in bone-metastatic castration-resistant prostate cancer with and without homologous repair gene defects, Eur Urol, 76, 170, 10.1016/j.eururo.2018.09.040 Nizialek, 2020, PARP inhibitors in metastatic prostate cancer: evidence to date, Cancer Manag Res, 12, 8105, 10.2147/CMAR.S227033